In contrast to Figure 6a and d, the group with higher ITGA3 expression exhibited significantly improved recurrence-free survival (RFS) (HR = 0.67 (0.61–0.75), Log-rank P = 1.2 × 10−13, Figure 6b) and DMFS (HR = 0.82 (0.7–0.96), Log-rank P = 0.016, Figure 6c) in BC compared to the group with lower ITGA3 expression. The gene discussed is ITGA3; the disease is breast cancer.